These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38096528)
1. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA. Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528 [TBL] [Abstract][Full Text] [Related]
2. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma. Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988 [TBL] [Abstract][Full Text] [Related]
3. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis. Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932 [TBL] [Abstract][Full Text] [Related]
4. Fascin expression in uterine smooth muscle tumors. Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633 [TBL] [Abstract][Full Text] [Related]
5. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study. Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146 [TBL] [Abstract][Full Text] [Related]
6. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors. Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689 [TBL] [Abstract][Full Text] [Related]
7. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039 [TBL] [Abstract][Full Text] [Related]
8. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond. Croce S; Chibon F Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852 [TBL] [Abstract][Full Text] [Related]
9. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710 [TBL] [Abstract][Full Text] [Related]
10. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma. Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023 [TBL] [Abstract][Full Text] [Related]
11. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification]. Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039 [TBL] [Abstract][Full Text] [Related]
12. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581 [TBL] [Abstract][Full Text] [Related]
13. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Ip PP; Cheung AN; Clement PB Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585 [TBL] [Abstract][Full Text] [Related]
14. Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors: A Clinicopathologic Analysis of 112 Cases With Emphasis on Potential Diagnostic Pitfalls. Lok J; Tse KY; Lee EYP; Wong RWC; Cheng ISY; Chan ANH; Leung CKL; Cheung ANY; Ip PPC Am J Surg Pathol; 2021 Sep; 45(9):1179-1189. PubMed ID: 34074809 [TBL] [Abstract][Full Text] [Related]
15. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma. Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613 [TBL] [Abstract][Full Text] [Related]
16. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases. Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968 [TBL] [Abstract][Full Text] [Related]
17. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. O'Neill CJ; McBride HA; Connolly LE; McCluggage WG Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074 [TBL] [Abstract][Full Text] [Related]
18. POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY. Tanabe Y; Hayashi T; Okada M; Aburatani H; Tonegawa S; Abiko K; Konishi I Georgian Med News; 2024 May; (350):42-48. PubMed ID: 39089269 [TBL] [Abstract][Full Text] [Related]
19. Smooth muscle tumors of the uterus: a practical approach. Toledo G; Oliva E Arch Pathol Lab Med; 2008 Apr; 132(4):595-605. PubMed ID: 18384211 [TBL] [Abstract][Full Text] [Related]
20. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas. Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]